News Column

New Findings on Hormones Described by Investigators at University of Washington

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting out of Seattle, Washington, by NewsRx editors, the research stated, "Androgen deprivation therapy (ADT) has been the standard of care for metastatic prostate cancer for decades; however, the choice of continuous or intermittent administration is a matter of debate. Two large phase III trials have reported results comparing these 2 forms of ADT administration."

Our news journalists obtained a quote from the research from the University of Washington, "The National Cancer Institute of Canada (NCIC) PR-7 trial studied men with an increasing prostate-specific antigen (PSA) level and no evidence of metastatic disease after definitive or salvage radiation therapy and radical prostatectomy. The Southwest Oncology Group 9346 trial studied men with newly diagnosed hormone-sensitive metastatic disease. The primary end point in both trials was overall survival with a noninferiority design. The NCIC trial showed that the overall survival in men treated with intermittent ADT was not inferior to that of men treated with continuous ADT, but the SWOG trial was inconclusive regarding noninferiority. Certain domains of quality of life were better in the intermittent arms of both trials. If using ADT in the setting of biochemical relapse, intermittent ADT should be strongly considered over continuous ADT, except perhaps in patients with Gleason score of 8 or higher. In men with metastatic disease, continuous ADT remains the standard of care, because the SWOG trial did not establish noninferiority of intermittent ADT with respect to survival."

According to the news editors, the research concluded: "However, for those with significant side effects from ADT, establishing the risk group, as determined by PSA value after 7 months of ADT or the presence of pain at diagnosis, may help guide the choice of intermittent versus continuous ADT in men with metastatic disease."

For more information on this research see: Intermittent Versus Continuous Androgen Deprivation Therapy. Journal of the National Comprehensive Cancer Network, 2014;12(5):727-733. Journal of the National Comprehensive Cancer Network can be contacted at: Harborside Press, 37 Main St, Cold Spring Harbor, NY 11724, USA (see also Drugs and Therapies).

Our news journalists report that additional information may be obtained by contacting C.S. Higano, University of Washington, Seattle Canc Care Alliance, Seattle, WA 98195, United States.

Keywords for this news article include: Seattle, Hormones, Washington, United States, Radiation Therapy, Drugs and Therapies, North and Central America, Androgens and Anabolic Steroids

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters